167 related articles for article (PubMed ID: 25742485)
21. Docetaxel and cisplatin induction chemotherapy with or without fluorouracil in locoregionally advanced nasopharyngeal carcinoma: A retrospective propensity score matching analysis.
Tao HY; Zhan ZJ; Qiu WZ; Liao K; Yuan YW; Zheng RH
Asia Pac J Clin Oncol; 2022 Apr; 18(2):e111-e118. PubMed ID: 33945215
[TBL] [Abstract][Full Text] [Related]
22. Brachytherapy boost in loco-regionally advanced nasopharyngeal carcinoma: a prospective randomized trial of the International Atomic Energy Agency.
Rosenblatt E; Abdel-Wahab M; El-Gantiry M; Elattar I; Bourque JM; Afiane M; Benjaafar N; Abubaker S; Chansilpa Y; Vikram B; Levendag P
Radiat Oncol; 2014 Mar; 9():67. PubMed ID: 24581393
[TBL] [Abstract][Full Text] [Related]
23. Prognostic Value of the Albumin-to-Alkaline Phosphatase Ratio before Chemoradiotherapy in Patients with Nonmetastatic Nasopharyngeal Carcinoma.
Yang L; Gao J; Zhou Y; Tao Z; He J; Yang J; Wang R; Zhang Y; Huang Y; Zhou L; Sun B
Chemotherapy; 2021; 66(1-2):40-46. PubMed ID: 33601377
[TBL] [Abstract][Full Text] [Related]
24. Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status.
Peng H; Chen L; Zhang Y; Guo R; Li WF; Mao YP; Tan LL; Sun Y; Zhang F; Liu LZ; Tian L; Lin AH; Ma J
Oncotarget; 2016 Apr; 7(17):24208-16. PubMed ID: 27008701
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial.
Cao SM; Yang Q; Guo L; Mai HQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Qiu F; Sun R; Chen QY; Huang PY; Luo DH; Hua YJ; Wu YS; Lv X; Wang L; Xia WX; Tang LQ; Ye YF; Chen MY; Guo X; Hong MH
Eur J Cancer; 2017 Apr; 75():14-23. PubMed ID: 28214653
[TBL] [Abstract][Full Text] [Related]
26. Ten-year outcomes of a randomised trial for locoregionally advanced nasopharyngeal carcinoma: A single-institution experience from an endemic area.
Huang PY; Zeng Q; Cao KJ; Guo X; Guo L; Mo HY; Wu PH; Qian CN; Mai HQ; Hong MH
Eur J Cancer; 2015 Sep; 51(13):1760-70. PubMed ID: 26093812
[TBL] [Abstract][Full Text] [Related]
27. Matched analysis of induction chemotherapy plus chemoradiotherapy versus induction chemotherapy plus radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a multicenter study.
Zhang B; Hu Y; Xiong RH; Pan YF; Xu QL; Kong XY; Cai R; Chen QQ; Tang HY; Jiang W
Oncotarget; 2017 Feb; 8(8):14078-14088. PubMed ID: 27845907
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of concurrent chemoradiotherapy in subgroups of stage III nasopharyngeal carcinoma: an analysis based on 10-year follow-up.
Wang L; Wu Z; Cheng W; Xie D; Lin F; Xia L; Su Y
Radiat Oncol; 2021 Nov; 16(1):215. PubMed ID: 34742304
[TBL] [Abstract][Full Text] [Related]
29. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis.
Xu C; Sun R; Tang LL; Chen L; Li WF; Mao YP; Zhou GQ; Guo R; Lin AH; Sun Y; Ma J; Hu WH
Oral Oncol; 2018 Mar; 78():37-45. PubMed ID: 29496056
[TBL] [Abstract][Full Text] [Related]
30. Effect of taxanes-based induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A large scale propensity-matched study.
Zhang LN; Gao YH; Lan XW; Tang J; OuYang PY; Xie FY
Oral Oncol; 2015 Oct; 51(10):950-6. PubMed ID: 26209065
[TBL] [Abstract][Full Text] [Related]
31. The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era.
Li PJ; Mo HY; Luo DH; Hu WH; Jin T
Oral Oncol; 2018 Oct; 85():95-100. PubMed ID: 30220326
[TBL] [Abstract][Full Text] [Related]
32. Induction Chemotherapy Plus Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma in Children and Adolescents: A Matched Cohort Analysis.
Li Y; Tang LQ; Liu LT; Guo SS; Liang YJ; Sun XS; Tang QN; Bei JX; Tan J; Chen S; Ma J; Zhao C; Chen QY; Mai HQ
Cancer Res Treat; 2018 Oct; 50(4):1304-1315. PubMed ID: 29334605
[TBL] [Abstract][Full Text] [Related]
33. Comparison of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in Lymph-Node-Stage III nasopharyngeal carcinoma based on propensity score-matching.
Liu ZC; Zeng KH; Gu ZB; Chen RP; Luo YJ; Tang LQ; Zhu KB; Liu Y; Sun XS; Zeng L
Radiother Oncol; 2023 Jan; 178():109421. PubMed ID: 36410548
[TBL] [Abstract][Full Text] [Related]
34. Asian Versus Non-Asian Outcomes in Nasopharyngeal Carcinoma: A North American Population-based Analysis.
Hamilton SN; Ho C; Laskin J; Zhai Y; Mak P; Wu J
Am J Clin Oncol; 2016 Dec; 39(6):575-580. PubMed ID: 24879476
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the efficacy between concurrent chemoradiotherapy with or without adjuvant chemotherapy for stage II nasopharyngeal carcinoma.
Chen J; Liu T; Sun Q; Jin T
Medicine (Baltimore); 2020 Jul; 99(29):e20443. PubMed ID: 32702809
[TBL] [Abstract][Full Text] [Related]
36. Effect of intensity-modulated radiotherapy versus two-dimensional conventional radiotherapy alone in nasopharyngeal carcinoma.
OuYang PY; Shi D; Sun R; Zhu YJ; Xiao Y; Zhang LN; Zhang XH; Chen ZY; Lan XW; Tang J; Gao YH; Ma J; Deng W; Xie FY
Oncotarget; 2016 May; 7(22):33408-17. PubMed ID: 27058901
[TBL] [Abstract][Full Text] [Related]
37. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost.
Ou X; Zhou X; Shi Q; Xing X; Yang Y; Xu T; Shen C; Wang X; He X; Kong L; Ying H; Hu C
Oncotarget; 2015 Nov; 6(35):38381-97. PubMed ID: 26485757
[TBL] [Abstract][Full Text] [Related]
38. The impairment of induction chemotherapy for stage II nasopharyngeal carcinoma treated with intensity-modulated radiotherapy with or without concurrent chemotherapy: A propensity score-matched analysis.
Lai Y; Wang C; Yang X; He S; Wang Y; Chen Y
Cancer Med; 2023 Feb; 12(3):2970-2978. PubMed ID: 36114787
[TBL] [Abstract][Full Text] [Related]
39. Non-metastatic stage IV nasopharyngeal carcinoma patients: analysis of the pattern of relapse and survival.
Ozyar E; Gurkaynak M; Yildiz F; Atahan IL
Radiother Oncol; 2004 Jul; 72(1):71-7. PubMed ID: 15236877
[TBL] [Abstract][Full Text] [Related]
40. Induction chemotherapy for the treatment of non-endemic locally advanced nasopharyngeal carcinoma.
Zhao L; Xu M; Jiang W; Pan H; Zang J; Luo S; Wang J; Zhou Y; Shi M
Oncotarget; 2017 Jan; 8(4):6763-6774. PubMed ID: 28036270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
